Processa Pharmaceuticals Inc (PCSA) USD0.0001
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development of drug products that are intended to provide treatment for patients who have unmet medical need condition that effects survival or the patient’s life and no treatment options. The Company has three drugs in various stages of clinical development. The Company’s advanced product candidate, PCS499, is an oral tablet that is a deuterated analog for metabolites of pentoxifylline (PTX or Trental). It has completed a Phase 2A trial for PCS499 and recruiting for a Phase 2 trial. PCS12852 is a potent and selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Its PCS6422 is an oral, potent, selective and irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD). The Company also has PCS11T, which is a lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.